Zobrazeno 1 - 10
of 128
pro vyhledávání: '"R R, French"'
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 1881
Over recent decades it has become increasingly apparent that malignant cells, including chronic lymphocytic leukemia (CLL) cells, do not exist in isolation. Rather they coalesce with numerous "normal" cells of the body and, in the case of CLL, inhabi
Publikováno v:
Methods in molecular medicine. 40
Monoclonal antibodies (mAbs) appear to offer many benefits for the treatment of cancer and in particular lymphoma (1). They are natural products that can be made with precise specificity and in almost unlimited amounts. In addition, mAbs can be selec
Autor:
R R, French
Publikováno v:
Methods in molecular medicine. 40
This protocol describes the production of bispecific F(ab')2 antibody derivatives (BsAbs) by the linking of two Fab' fragments via their hinge region SH groups using the bifunctional crosslinker o-phenylenedimaleimide (o-PDM) as described by Glennie
Autor:
F. Oden, Iglika K Djoumerska-Alexieva, F. Berthold, S. V. Dixon, S. S. Wijayaweera, Sandra Hervas-Stubbs, J. H. J. Kim, Lim Sean, M. Jensen, M. Koch, D. A. Johnston, Tchavdar L. Vassilev, Ariane Groth, A. Morales, Claude H.T. Chan, A. Martinez, T. Boeldicke, Ignacio Melero, Jordan D. Dimitrov, Alexei V. Salnikov, A. Teijeira, K. L. Cox, J. S. Verbeek, Ingrid Herr, M. Lipp, E. Ryschich, N. Nishimoto, M. Jure-Kunkel, Asis Palazon, A. Rouzaut, F. Wilde, L. Ochoa, C. Ochoa, P. Johnson, Stephen A. Beers, M. W. Büchler, M. J. Glennie, Juan Dubrot, T. C. Jarrett, J. P. Kerr, Gerhard Moldenhauer, Sébastien Lacroix-Desmazes, Mark S. Cragg, H. Panjideh, L. Grosse-Hovest, R. R. French, A. Kopacek, Srinivas V. Kaveri
Publikováno v:
International Immunology. 22:ii169-ii170
Autor:
F. Oden, Claude H.T. Chan, Mark S. Cragg, J. H. J. Kim, M. Koch, Lim Sean, M. W. Büchler, Iglika K Djoumerska-Alexieva, Sébastien Lacroix-Desmazes, M. Lipp, M. J. Glennie, Ingrid Herr, R. R. French, Gerhard Moldenhauer, J. S. Verbeek, S. S. Wijayaweera, L. Grosse-Hovest, S. V. Dixon, H. Panjideh, Asis Palazon, Srinivas V. Kaveri, Tchavdar L. Vassilev, A. Morales, A. Martinez, A. Rouzaut, E. Ryschich, Jordan D. Dimitrov, Stephen A. Beers, Juan Dubrot, A. Kopacek, T. Boeldicke, A. Teijeira, Ignacio Melero, L. Ochoa, P. Johnson, C. Ochoa, J. P. Kerr, F. Berthold, Ariane Groth, T. C. Jarrett, N. Nishimoto, M. Jure-Kunkel, F. Wilde, M. Jensen, Sandra Hervas-Stubbs, D. A. Johnston, Alexei V. Salnikov, K. L. Cox
Publikováno v:
International Immunology. 22:v23-v24
Autor:
L. Bertoli, N. Antoine, A. L. White, K. L. Cox, J. Boniver, K. Neubert, H. Kubagawa, M. van Egmond, D. Kang, H. Mori, N. Jacobs, R. S. Davis, B. Clénanceau, R. Beelen, M. S. Cragg, P. Delvenne, L. van der Steen, C. Chan, C. Lehmann, T. Motohashi, I. Torii, Y. Kubagawa, S. Barnes, S. A. Beers, A. Reschner, S. Oka, N. Smyth, D. Dudziak, I. Langers, B. Lau, E. Dortu, J. Bakema, H. Takatsu, T. Kitamura, F. J. Li, J. S. Verbeek, M. J. Glennie, V. Renoux, A. L. Tutt, M. Thiry, A. Roghanian, F. Nimmerjahn, J. Y. Wang, J. H. J. Kim, H. Ohno, L. F. Bertoli, E. L. Williams, R. R. French, J. C. Barton, C. Tuk, L. S. Wilson, B. Sheth, M. S. Gragg, G. L. Gartland, E. Takayama, C. H. T. Chan, S. Verbeek
Publikováno v:
International Immunology. 22:v16-v17
Autor:
R R, French
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 80
Publikováno v:
Cancer research. 53(13)
A panel of bispecific F(ab')2 antibodies (BsAb) have been constructed for delivering the ribosome-inactivating protein saporin to human B cell lymphoma. Each derivative was prepared with specificity for saporin and CD19, CD22, CD37, or immunoglobulin
Publikováno v:
International journal of cancer. Supplement = Journal international du cancer. Supplement. 7
Results are presented showing the use of bispecific F(ab')2 antibodies (bsAbs) in the delivery of saporin for the treatment of 2 human B-cell malignancies. BsAbs delivering saporin through CD22, but not through CD19, were effective at inhibiting the
Publikováno v:
Cancer research. 51(9)
We report that selected combinations of two or more monoclonal bispecific F(ab')2 antibodies (BsAbs) far outperform single derivatives in the delivery of the ribosome-inactivating protein, saporin, to guinea pig L2C leukemic cells. Throughout the wor